Passage Bio, Inc. (NASDAQ: PASG) had its price target lowered by analysts at Chardan Capital from $7.00 to $6.00. They now have a "buy" rating on the stock.
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
Passage Bio to Participate in Upcoming Investor Conferences